哈药股份(600664.SH)所属企业药品通过一致性评价

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (哈药股份) has received approval from the National Medical Products Administration for two formulations of injectable cefoperazone sodium and sulbactam sodium, indicating a significant advancement in its product portfolio and compliance with quality and efficacy standards for generic drugs [1] Group 1 - The company’s subsidiary, Harbin Pharmaceutical Group Pharmaceutical Factory, has been granted a "Drug Supplement Application Approval Notice" for two formulations of injectable cefoperazone sodium and sulbactam sodium [1] - The approved products include four specifications that have passed the consistency evaluation of quality and efficacy for generic drugs [1]